An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn how treatment with acetyl-L-carnitine (ALCAR) will
affect the hearts of patients with Friedreich's Ataxia as well as how it may affect other
symptoms of Friedreich's Ataxia such as difficulties with balance, walking, or upper arm
function.